Clinical Trials Sponsored by Halozyme Therapeutics

Total 6218 results

Halozyme Therapeutics

Completed

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
Halozyme Therapeutics

Completed

Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
Halozyme Therapeutics

Completed

A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone

Healthy

United States
Halozyme Therapeutics

Completed

Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors

Solid Tumor

United States
Halozyme Therapeutics

Completed

INFUSE Morphine Study (INFUSE)

Pain

United States
Halozyme Therapeutics

Terminated

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Carcinoma

Korea, Republic of, United States, Taiwan, United Kingdom, Israel, France, Germany, Netherlands, Canada, Spain, Australia, Brazil, Belgium, Croatia, Czechia, Denmark, Estonia, Hungary, Italy, Latvia, Lithuania, Poland
Halozyme Therapeutics

Completed

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

Gastric Cancer | NSCLC

United States
Halozyme Therapeutics

Completed

Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
Halozyme Therapeutics

Completed

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

Type 1 Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20

Healthy Volunteers

United States
Halozyme Therapeutics

Completed

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
Halozyme Therapeutics

Completed

Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers

Healthy

United States
Halozyme Therapeutics

Completed

Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors (PEG)

Solid Tumor

United States
Halozyme Therapeutics

Completed

A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase

Healthy
Halozyme Therapeutics

Completed

A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects

Healthy

United States
Halozyme Therapeutics

Completed

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

Dermatitis, Allergic Contact

United States
Halozyme Therapeutics

Completed

Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer

Bladder Cancer

United States
Halozyme Therapeutics

Terminated

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic | Gallbladder Adenocarcinoma

United States, Korea, Republic of, Thailand
Halozyme Therapeutics

Terminated

A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC (PRIMAL)

Non-small Cell Lung Cancer

United States
Halozyme Therapeutics

Completed

A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20) (HALO-117-406)

Type 1 Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

Stage IV Pancreatic Cancer

United States, Russian Federation
Halozyme Therapeutics

Completed

Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone

Risk Factors for or a Diagnosis of Osteoporosis

United States
Halozyme Therapeutics

Completed

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type II

United States
Halozyme Therapeutics

Completed

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer (IPOP)

Superficial Bladder Cancer

United States
Halozyme Therapeutics

Completed

Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human Hyaluronidase

Rheumatoid Arthritis
Pfizer
Halozyme Therapeutics

Terminated

Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase

Healthy | Hypercholesterolemia

Belgium
Shire
Halozyme Therapeutics

Completed

A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase

Hereditary Angioedema

United States
Eisai Inc.
Halozyme Therapeutics

Terminated

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer

United States
Halozyme Therapeutics
Baxter Healthcare Corporation

Completed

Subcutaneous Rehydration Compared to Intravenous Rehydration (PEDs-II)

Dehydration

United States
Baxter Healthcare Corporation
Halozyme Therapeutics

Terminated

Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A) (INFUSE-AT1A)

Dehydration

United States
Halozyme Therapeutics
Baxter Healthcare Corporation

Completed

Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex) (INFUSE-NSLR)

Healthy

United States
Baxter Healthcare Corporation
Halozyme Therapeutics

Withdrawn

Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED) (INFUSE-TM)

Dehydration
Baxter Healthcare Corporation
Halozyme Therapeutics

Completed

Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration (INFUSE-Cftrx)

Healthy
Baxter Healthcare Corporation
Halozyme Therapeutics

Completed

Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT)

Dehydration

United States
Baxter Healthcare Corporation
PPD; Halozyme Therapeutics

Completed

Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children (INFUSE-PR)

Dehydration
Hoffmann-La Roche
BioLineRx, Ltd.; Halozyme Therapeutics

Active, not recruiting

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

United States, United Kingdom, Australia, Korea, Republic of, Taiwan, Israel, Spain
Gulam Manji
Genentech, Inc.; Halozyme Therapeutics

Terminated

Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma (NEOiPANC)

Pancreatic Ductal Adenocarcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI); Halozyme Therapeutics

Completed

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma

United States
Abramson Cancer Center of the University of Pennsylvania
Halozyme Therapeutics

Withdrawn

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

United States
Memorial Sloan Kettering Cancer Center
Halozyme Therapeutics; Miami Cancer Institute

Active, not recruiting

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Pancreatic Cancer | Advanced Pancreatic Ductal Adenocarcinoma

United States
Alizyme

Terminated

Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Constipation-Predominant Irritable Bowel Syndrome

United States
Alizyme

Completed

Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis

Ulcerative Colitis

Spain, Belgium, Denmark, United Kingdom, South Africa, Israel, France, Australia, Sweden, Italy, Poland, Czech Republic, Germany, Hungary, Russian Federation
Alizyme

Completed

Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome

United Kingdom
Alizyme

Completed

Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis

Mucositis

United Kingdom
Alizyme

Completed

Efficacy and Safety of ATL-962 in Obese Diabetics

Obesity | Non-Insulin-Dependent Diabetes Mellitus

Finland, Netherlands, Denmark, United Kingdom, Sweden

3

Subscribe